Healthcare Industry News: Magnetic Resonance Imaging
News Release - January 10, 2006
CAD Sciences Announces the Creation of the First Ever Category III CPT Code for Breast MRI CADWHITE PLAINS, N.Y., Jan. 10 (HSMN NewsFeed) -- CAD Sciences announces the creation of the first ever Category III Current Procedural Terminology (CPT) code that can be used for Breast MRI CAD.
+*0159T Computer aided detection, including computer algorithm analysis of MRI data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation, breast MRI (List separately in addition to code for primary procedure) (Use 0159T in conjunction with 76093, 76094)This new CPT code was established by the American Medical Association (AMA) through a formal process initiated by the filing of a Coding Change Request Form by CAD Sciences. One of the major factors considered in the approval of a new procedure or service by the AMA centers on the existence of validation through clinical trials. CAD Sciences' CPT code submission was substantiated with published results of clinical trials exhibiting the efficacy of the company's Pharmacokinetic Analysis technology for breast. The CPT code announcement is consistent with the Company's strong reputation for innovation as demonstrated by the recent development of its Full-Time-Point (fTP) Pharmacokinetic Analysis platform for lesion characterization in MRI, a technology that is unparalleled in the industry and has rendered competing systems obsolete.
"CAD Sciences' involvement with this process has led to the historic creation of a Category III code that will allow radiologists the opportunity to properly submit Breast MRI reimbursement claims. Consequently, usage may therefore be documented over time with the goal of converting the Category III to a more permanent Category I code", said Andreas Muehler, M.D., President of CAD Sciences.
Category III codes are designated for emerging services or procedures for which data are required to establish a Category I code. The new Category III code was implemented on January 1, 2006 by the AMA and can be found on the AMA's website (http://www.ama-assn.org). Category III codes are intended for data collection in order to substantiate usage by clinicians or in the FDA approval process.
"It is important for users of CAD Sciences' pharmacokinetic analysis software to utilize this new code as a way to further validate clinical solutions in the fight against breast cancer," said Raymond Joslin, Chairman and CEO of CAD Sciences.
The new Category III CPT code has not been assigned Relative Value Units (RVUs), which drive the standardization of reimbursement. For now, payment for the use of this code will be based on existing policies of individual payors instead of the fee schedule published yearly by the AMA.
About CAD Sciences:
Founded in March 2002 and formerly known as 3TP Imaging Sciences, CAD Sciences is the technology leader in the advancement of computer-assisted modeling of contrast enhancement in MR imaging of cancer. From its base in White Plains, NY, the Company designs and internationally distributes certain intellectual property in CAD (Computer Assisted Diagnosis) and MRA (Magnetic Resonance Angiography) software for medical imaging. The Company's Server2(TM) and WorkSpace(TM) software platforms are currently used by radiologist customers to facilitate the analysis, interventional planning and reporting of breast and prostate MRI. Together these products automate MRI image processing and provide higher quality imaging studies, lower facility costs, increased revenue streams for radiology practices as well as improved analysis and reporting tools for physicians. In addition, the Company is the sole distributor of Machnet breast biopsy intervention devices and magnetic resonance breast and carotid coils.
More information about the Company or its technology can be obtained by visiting our website at http://www.cadsciences.com or by calling our office at (877) 387-4387.
Source: CAD Sciences
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.